Upcoming Obicetrapib Phase 3 Data at ACC.26 Might Change The Case For Investing In NewAmsterdam Pharma (NAMS) [Yahoo! Finance]
NewAmsterdam Pharma Company N.V. - Ordinary Shares (NAMS)
Company Research
Source: Yahoo! Finance
at the American College of Cardiology Annual Scientific Session (ACC.26) in New Orleans on March 28–30, 2026, including results from the Phase 3 BROADWAY trial and pooled Phase 3 safety data. The planned presentations spotlight obicetrapib's potential to pair LDL-lowering efficacy with a placebo-like safety profile and preserved kidney function in high-risk cardiovascular patients, positioning it as a potential next-generation option alongside statins and other non-statin therapies. Against this backdrop, we'll examine how upcoming Phase 3 safety and kidney-function data for obicetrapib could shape NewAmsterdam's investment narrative. Find 62 companies with promising cash flow potential yet trading below their fair value What Is NewAmsterdam Pharma's Investment Narrative? To own NewAmsterdam Pharma, you need to believe obicetrapib can become a meaningful new LDL-lowering option in a crowded cardiometabolic market, and that management can convert late-stage data into regulato
Show less
Read more
Impact Snapshot
Event Time:
NAMS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NAMS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NAMS alerts
High impacting NewAmsterdam Pharma Company N.V. - Ordinary Shares news events
Weekly update
A roundup of the hottest topics
NAMS
News
- NewAmsterdam Pharma Announces Three Presentations at the 2026 American College of Cardiology Annual Scientific Session [Yahoo! Finance]Yahoo! Finance
- NewAmsterdam Pharma Announces Three Presentations at the 2026 American College of Cardiology Annual Scientific SessionGlobeNewswire
- NewAmsterdam Pharma (NAMS) is now covered by Truist Financial Corporation. They set a "buy" rating and a $57.00 price target on the stock.MarketBeat
- NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswire
- NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in MarchGlobeNewswire
NAMS
Sec Filings
- 3/12/26 - Form 4
- 3/11/26 - Form 144
- 3/10/26 - Form 4
- NAMS's page on the SEC website